BridgeBio Pharma (NASDAQ:BBIO) Given New $94.00 Price Target at JPMorgan Chase & Co.

BridgeBio Pharma (NASDAQ:BBIO) had its price objective increased by JPMorgan Chase & Co. from $89.00 to $94.00 in a report issued on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

Other equities research analysts have also issued reports about the company. Wells Fargo & Company boosted their target price on BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Barclays assumed coverage on shares of BridgeBio Pharma in a report on Wednesday, January 28th. They set an “overweight” rating for the company. Oppenheimer dropped their target price on shares of BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating on the stock in a report on Wednesday, February 25th. Raymond James Financial set a $89.00 target price on shares of BridgeBio Pharma and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. Twenty-three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $83.35.

BridgeBio Pharma Stock Up 13.2%

BBIO stock opened at $74.32 on Tuesday. The company has a market capitalization of $14.41 billion, a price-to-earnings ratio of -19.66 and a beta of 1.13. BridgeBio Pharma has a 12 month low of $28.33 and a 12 month high of $84.94. The firm has a 50 day moving average of $73.42 and a two-hundred day moving average of $65.74.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The business had revenue of $154.18 million during the quarter, compared to the consensus estimate of $150.71 million. During the same quarter in the prior year, the business posted ($1.40) EPS. BridgeBio Pharma’s quarterly revenue was up 2521.2% on a year-over-year basis. On average, research analysts expect that BridgeBio Pharma will post -3.67 EPS for the current fiscal year.

Insider Activity

In other BridgeBio Pharma news, CFO Thomas Trimarchi sold 13,600 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $74.72, for a total value of $1,016,192.00. Following the sale, the chief financial officer owned 336,585 shares of the company’s stock, valued at $25,149,631.20. The trade was a 3.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Andrea Ellis sold 64,921 shares of BridgeBio Pharma stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $64.87, for a total transaction of $4,211,425.27. Following the sale, the director owned 18,589 shares in the company, valued at approximately $1,205,868.43. This trade represents a 77.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 227,095 shares of company stock valued at $16,099,240. 18.20% of the stock is owned by insiders.

Institutional Investors Weigh In On BridgeBio Pharma

Several large investors have recently modified their holdings of the stock. Invesco Ltd. grew its stake in shares of BridgeBio Pharma by 23.0% in the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock valued at $369,547,000 after purchasing an additional 902,648 shares during the period. Mackenzie Financial Corp grew its position in BridgeBio Pharma by 8.9% in the fourth quarter. Mackenzie Financial Corp now owns 54,495 shares of the company’s stock valued at $4,105,000 after acquiring an additional 4,448 shares during the period. XTX Topco Ltd grew its position in BridgeBio Pharma by 162.4% in the fourth quarter. XTX Topco Ltd now owns 13,169 shares of the company’s stock valued at $1,007,000 after acquiring an additional 8,150 shares during the period. VARCOV Co. acquired a new position in BridgeBio Pharma during the fourth quarter worth $340,000. Finally, Voloridge Investment Management LLC raised its stake in BridgeBio Pharma by 377.4% during the fourth quarter. Voloridge Investment Management LLC now owns 638,883 shares of the company’s stock worth $48,868,000 after acquiring an additional 505,051 shares in the last quarter. 99.85% of the stock is currently owned by institutional investors.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: JPMorgan raised its price target to $94 and kept an “overweight” rating, implying meaningful upside from current levels; this large-bank upgrade likely boosted investor demand. JPMorgan raises price target
• Positive Sentiment: William Blair initiated coverage with an “outperform” rating, adding institutional analyst support and fresh buy-side attention. William Blair starts coverage
• Positive Sentiment: HC Wainwright revised estimates aggressively, forecasting FY2027 EPS of $1.83 and maintaining a $100 target — another high-profile bullish projection that supports investor optimism. HC Wainwright estimate
• Positive Sentiment: Media coverage is highlighting BridgeBio’s rare-disease pipeline as a growth catalyst, which can lift sentiment and attract speculative interest in the biotech name. BridgeBio pipeline article
• Neutral Sentiment: Reports flagged a “large increase” in short interest, but the published data shows zero shares/NaN and a days-to-cover of 0.0 — the short-interest figures appear erroneous or incomplete, so they offer no clear directional signal today.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.